

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\067\2023-24

Date: 30.10.2023

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001
Scrip Code No.524394

Asst Vice President
National Stock Exchange of India Limited
"Exchange Plaza", Bandra
Kurla Complex, Bandra (E)
Mumbai – 400051
Trading Symbol: VIMTALABS

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 30th September 2023.

Pursuant to Regulation 30 of SEBI (Listing obligations and disclosure requirements) 2015, please find attached the press release in connection with announcement of unaudited Standalone and Consolidated Financial Results for the 2nd quarter / half year ended 30th September 2023.

This is for your information and records.

Thanking you,

Yours faithfully,
for VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary

Attachments: as above.



Vimta Labs Limited Reports Q2 & H1 FY24 Results

**H1 FY24 Total Income at Rs. 1,595 Mn,
EBITDA margins at 27.1%; PAT margin at 11.6%**

Hyderabad, October 30, 2023: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and half year ended September 30, 2023.

Consolidated Financial Results – Q2 & H1 FY24

Particulars (Rs. Mn)	Q2FY24	Q2FY23	YoY	H1FY24	H1FY23	YoY
Total Income	754	806	(6.4%)	1,595	1,606	(0.7%)
EBITDA (including other income)	179	261	(31.4%)	432	509	(15.3%)
EBITDA Margin	23.8%	32.4%		27.1%	31.7%	
PAT	63	132	(52.1%)	185	252	(26.6%)
PAT Margin	8.4%	16.4%		11.6%	15.7%	
Basic EPS	2.9	6.0		8.4	11.4	

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: *"The downtrend in our income has primarily stemmed from the Pharma and Food business, which saw decreased demand and lower volumes respectively. Conversely, our E&E business continues to perform well, with Environment and Diagnostics remained stable.*

Given the headwinds from the broader economic uncertainties, we acknowledge the external challenges. However, our ongoing dialogues with clients along with the stability provided by our long-term contracts and revenue visibility for the H2 FY24 keeps me optimistic of delivering growth in FY24."

Key Results Highlights for the Q2 & H1 FY24 (Consolidated):

- ✓ Total Income for Q2FY24 was at Rs. 754 Mn a de-growth of 6.4% YoY
- ✓ EBITDA for Q2FY24 was Rs. 179 Mn a decline of 31.4% YoY; EBITDA margin was at 23.8%
- ✓ Total Income for H1FY24 was at Rs. 1,595 Mn a de-growth of 0.7% YoY
- ✓ EBITDA for H1FY24 was Rs. 432 Mn a decline of 15.3% YoY; EBITDA margins at 27.1%
- ✓ Cash and Cash equivalents at Rs. 262 Mn as of 30th September 2023
- ✓ Cash flow From Operations at Rs. 268 Mn for H1FY24; H1FY24 Capex at Rs. 421 Mn
- ✓ Debt to Equity ratio 0.07

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides clinical diagnostic services and environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

<p>Investor Relations at Vimta Labs Narahai Naidu Dodda, CFO Narahai.Dodda@vimta.com</p> <p>Ernst & Young Mr. Rahul Thakur Rahul.thakur@in.ey.com</p> <p>Mr. Advait Bhadekar Advait.bhadekar@in.ey.com</p>	<p>Registered Office Plot Number 142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com</p>
--	---